Shots:

• Fosun Pharma’s FN-1501 is a novel drug candidate with inhibiting FLT3 and CDK while its IND has been approved by the US FDA and NMPA in Oct & Dec 2017 respectively
• The FDA’s ODD is granted supporting the development of drugs for safe and effective treatment- diagnosis or prevention of rare diseases or disorders that affect fewer than 200-000 people in the US. Additionally- the designation also provides various development incentives- including tax credits for qualified clinical testing- an exemption from FDA application fees- and a 7yrs. period of marketing exclusivity in the US- if approved
• FN-1501 is currently underway for P-I to treat leukemia and solid tumors in the US- Australia- and Mainland China

Click here to­ read full press release/ article | Ref: Fosun Pharma | Image: Behance